Key Points
- Insider Yvonne Hui sold 1,327 shares of Phreesia on April 17 at an average price of $9.28 for $12,314.56 (following a 10,063‑share sale on April 16), reducing her holding to 24,664 shares; the transactions were executed under a Rule 10b5-1 trading plan.
- Phreesia reported Q1 EPS of $0.02, missing estimates while revenue rose 15.9% to $127.07 million; the stock trades around $9.33 (50‑day MA $10.82, 200‑day MA $16.01) and carries a consensus "Moderate Buy" with a $20.82 target amid recent price‑target cuts.
Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 1,327 shares of Phreesia stock in a transaction on Friday, April 17th. The shares were sold at an average price of $9.28, for a total value of $12,314.56. Following the sale, the insider directly owned 24,664 shares in the company, valued at $228,881.92. The trade was a 5.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Yvonne Hui also recently made the following trade(s):
- On Thursday, April 16th, Yvonne Hui sold 10,063 shares of Phreesia stock. The shares were sold at an average price of $9.08, for a total value of $91,372.04.
Phreesia Stock Down 1.1%
Shares of Phreesia stock opened at $9.33 on Wednesday. The business's fifty day moving average price is $10.82 and its two-hundred day moving average price is $16.01. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.53. The company has a market capitalization of $566.59 million, a P/E ratio of 310.83 and a beta of 0.86. Phreesia, Inc. has a 1-year low of $7.77 and a 1-year high of $32.76.
Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The business had revenue of $127.07 million for the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm's revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.11) EPS. As a group, research analysts forecast that Phreesia, Inc. will post 0.36 EPS for the current year.
Institutional Trading of Phreesia
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Phreesia by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company's stock valued at $134,177,000 after purchasing an additional 437,462 shares during the period. New York State Common Retirement Fund boosted its position in shares of Phreesia by 727.1% in the 3rd quarter. New York State Common Retirement Fund now owns 136,856 shares of the company's stock valued at $3,219,000 after purchasing an additional 120,309 shares during the period. Greenhouse Funds LLLP boosted its position in shares of Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company's stock valued at $91,317,000 after purchasing an additional 557,265 shares during the period. Bessemer Group Inc. boosted its position in shares of Phreesia by 1,065.9% in the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company's stock valued at $13,043,000 after purchasing an additional 506,954 shares during the period. Finally, Capricorn Fund Managers Ltd acquired a new position in shares of Phreesia in the 3rd quarter valued at $11,395,000. Institutional investors and hedge funds own 92.10% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on PHR shares. Wells Fargo & Company lowered their price target on Phreesia from $30.00 to $25.00 and set an "overweight" rating on the stock in a research report on Thursday, March 26th. KeyCorp cut their price objective on Phreesia from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, April 13th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $16.00 price objective (down from $24.00) on shares of Phreesia in a report on Tuesday, March 31st. Royal Bank Of Canada initiated coverage on Phreesia in a report on Friday, January 9th. They issued a "moderate buy" rating and a $26.00 price objective for the company. Finally, DA Davidson cut their price objective on Phreesia from $35.00 to $30.00 and set a "buy" rating for the company in a report on Friday, January 23rd. Twelve equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $20.82.
Read Our Latest Stock Report on PHR
About Phreesia
(
Get Free Report)
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
